A biomarker study to evaluate dolcanatide to prevent colorectal cancer in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2018
Price : $35 *
At a glance
- Drugs Dolcanatide (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics
- 07 Aug 2018 Status changed from planning to recruiting, according to a Synergy Pharmaceuticals Inc media release.
- 17 May 2018 New trial record
- 10 May 2018 Acccording to a Synergy Pharmaceuticals media release, the company has initiated a partnership with National Cancer Institute (NCI) to collaborate on this NCI-funded and managed study.